EP Patent

EP3626253A2 — Stable formulations of linaclotide

Assigned to Allergan Pharmaceuticals International Ltd · Expires 2020-03-25 · 6y expired

What this patent protects

The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.

USPTO Abstract

The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.

Drugs covered by this patent

Patent Metadata

Patent number
EP3626253A2
Jurisdiction
EP
Classification
—
Expires
2020-03-25
Drug substance claim
No
Drug product claim
No
Assignee
Allergan Pharmaceuticals International Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.